Inclusion Criteria:  Patients who are clinically diagnosed with stage IV NSCLC; Patients who submitted samples for molecular testing using the OncoScreen Plus panel and PD-L1 (22C3) immunohistochemistry test at baseline; Patients with negative results for sensitizing mutations for 6 genes, including EGFR, ALK, ROS1, BRAF, MET exon 14 skipping, and RET; Patients without contraindications for immunotherapy; Patients who are 18 years or older at the time of signing the informed consent form; Patients with life expectancy of at least 12 weeks; Patients with ECOG score of 0 or 1;  Patients with adequate organ function defined by the following criteria:  Absolute neutrophil count ≥ 1.5109/L; Platelets ≥ 90109/L; Hemoglobin ≥ 9.0g/dL; Albumin levels ≥2.8 g/L; Total serum bilirubin ≤ 1.5 the upper limit of normal (ULN); for patients with liver metastases, total bilirubin ≤ 2 ULN; Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 ULN; for patients with liver metastases, ALT and AST ≤ 5ULN; Serum creatinine ≤ 1.5 ULN; International normalized ratio (INR) or plasma prothrombin time (PT) ≤1.5ULN.  Exclusion Criteria:  Patients with other concurrent tumors; Patients with other concurrent medical conditions that may affect their follow-up and short-term survival; Patients with any history of immunotherapy; Patients with any history of chemotherapy, radiotherapy or other anti-tumor treatments; Patients with heart function classified as New York Heart Association (NYHA) class III or IV; Patients with peripheral nerve disease; Patients with confirmed hearing loss; Patients with other conditions deemed unsuitable for enrollment by the researchers.